Advancing Bispecific Antibodies and Combination Therapy to the Clinic

Bispecific antibodies continue to dominate the biologics landscape and their advancement to the clinic is showing extraordinary promise. The application of innovative approaches through precise activation, gating, and masking approaches is giving better control of targeting and efficacy. Insights into how these constructs behave in vivo and how to mitigate toxicity and off-target effects will be reviewed from preclinical and clinical studies. The 12th Annual Advancing Bispecific Antibodies and Combination Therapy to the Clinic conference at the PEGS Boston Summit brings together the leading researchers in the industry to strategize on the safety and efficacy of new constructs, review the latest clinical results, and expand their use into areas beyond oncology.